Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer
Status:
Not yet recruiting
Trial end date:
2023-01-10
Target enrollment:
Participant gender:
Summary
This phase II trial investigates the effect of sitravatinib and nivolumab in treating
patients with clear cell renal cell cancer that has spread to other places in the body
(metastatic/advanced). Sitravatinib may stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as
nivolumab, may help the body's immune system attack the cancer, and may interfere with the
ability of tumor cells to grow and spread. Giving sitravatinib and nivolumab may kill more
tumor cells.